JPMorgan creates healthcare venture capital team

JPMorgan has launched a healthcare venture capital team targeting the life sciences. 

The team, Life Sciences Private Capital, plans to invest in early- to later-stage healthcare companies and seeks to capitalize on innovation in areas such as genetic medicine, autoimmune diseases, cardiometabolic diseases and rare disorders, according to a Nov. 1 press release from JPMorgan. 

A group of advisers will assist the investment team, meeting regularly and providing guidance as needed to help portfolio companies. The advisers are:

  • Laurie Glimcher, MD, president and CEO of the Boston-based Dana-Farber Cancer Institute

  • Jeffrey Leiden, MD, PhD, executive chair and former CEO of drug developer Vertex Pharmaceuticals

  • Frederic Moll, MD, a robotic surgery pioneer and entrepreneur who is now an executive at Johnson & Johnson

  • Stephen Oesterle, MD, former senior vice president for medicine and technology at medical-technology company Medtronic

  • Robert Stockman, co-founder and former CEO of medical device company REVA Medical

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars